HilleVax, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Operating expenses:
Research and development (includes related party amounts of $22 and $362, respectively)
In-process research and development - related party
In-process research and development
General and administrative
Restructuring and impairment charges
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense (includes related party amounts of $0 and $717, respectively)
Change in fair value of convertible promissory notes (includes related party amounts of $0 and $13,196, respectively)
Change in fair value of warrant liabilities - related party
Interest expense
Other income
Total other income
Net loss
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities
Pension and other postemployment benefits
Total comprehensive loss
Net loss per share, basic
Net loss per share, diluted
Weighted-average shares of common stock outstanding, basic
Weighted-average shares of common stock outstanding, diluted

Comments